Showing results (351-360 of 650) with videos related to
Sort By:
Pageof 65
Nature Cancer|October 17, 2022
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complexYu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, et al.Nature Cancer|May 26, 2025
Skeletal muscle endothelial dysfunction through the activin A-PGC1α axis drives progression of cancer cachexiaYoung-Mee Kim, Mark A Sanborn, Shaluah Vijeth, et al.Nature Cancer|June 5, 2025
The current and emerging immunotherapy paradigm in small-cell lung cancerKang Qin, Carl M Gay, Lauren A Byers, et al.Nature Cancer|November 2, 2025
Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trialSijia Gu, Qiyu Luo, Yalei Zhang, et al.Nature Cancer|June 27, 2025
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical featuresIlaria Iacobucci, Andy G X Zeng, Qingsong Gao, et al.Nature Cancer|July 7, 2025
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophagesGiulia Petroni, Claudia Galassi, Kenneth H Gouin, et al.Nature Cancer|June 24, 2025
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer typesGil Awada, Tina Cascone, Michiel S van der Heijden, et al.Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.Nature Cancer|January 16, 2026
Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapyXiaohong Chen, Minqi Yang, Yuxuan Chen, et al.Nature Cancer|April 18, 2025
UnitedMet harnesses RNA-metabolite covariation to impute metabolite levels in clinical samplesAmy X Xie, Wesley Tansey, Ed ReznikPageof 65